- Email: [email protected]
P-2 Prognostic value of bone marrowblast cells and karyotype in myelodysplastic syndrome
$25
Posters
Etiology, Prognosis
•
RELATIONSHIP BETWEEN GSTT1, GSTM1 AND NQO1 GENES POLYMORPHISMS AND MYELODYSPLASTIC S Y M D R O M E S
Z. Xiao*, L. Yang, X. Zou, Y. Zhang, M. Zhang, Y. Hao. Institute of Hematology, CA34S & PUMC, China *E-maih [email protected] To investigate the impact of GSTM1, GSTT1 and NQO1 genotypes on the myelodysplastic syndromes (MDS) susceptibility and chromosome abnormalities of MDS, we analyzed gene polymorphisms of glutathione Stransferase (GST)-M1 and GSTT1, and NAD(P)H: quinone oxidoreductase (NQO1), the enzymes of which are capable of metabolizing anticancer drugs, in 52 MDS patients and 241 controls by PCR or PCR-RFLP. The incidence of GSTT1 (67.3%) and GSTM1 (80%) null genotype were significantly increased in MDS patients as compared to controls (44.8% and 52.7%, respectively) (p 0.001 and p<0.001, respectively), in individuals with the GSTT1 and GSTM1 null genotype, the odds ratios for disease risk were elevated to 2.873 (95%CI: 1.491 5.537) and 3.591 (95%CI: 1.71%7.508), respectively. A significantly increased frequency of GSTT1 null genotype was found among MDS patients with normal karyotype compared to controls (P 0.005, OR 5.336), while the frequency of GSTM1 null genotype was significantly higher in MDS patients with chromosome abnormalities compared to controls (P 0.003, OR 3.740). There is no difference of the incidence of NQO1 genotypes between MDS patients and controls. These results suggest that determination of the GSTM1 and GSTT1 genotypes may be used as a stratification marker to predicate high-risk individuals for MDS and the chromosome abnormalities in MDS patients.
•
PROGNOSTIC VALUE OF BONE MARROW BLAST CELLS AND KARYOTYPE IN MYELODYSPLASTIC SYNDROME
S.V. Gritsaev*, I.S. Martinkevitch, S.A. Tyranova, M.R Bakaja, K.M. Abdulkadirov. Russian Institute of Hematology, Russia *E-maih haemat ology@at lant.ru The aim of the work was to examine the predictive value of the bone marrow blast cells and karyotype as the markers
of leukemic evolution. We reviewed retrospectively 72 previously diagnosed cases of primary MDS. The diagnoses were established according to the WHO criteria. Twentythree patients (31.9%) progressed to AML with the median interval of 9 months (range 1 74 months). Acute leukemia evolution of 10 patients (43.5%) was observed at the first 6 months after the diagnosis and four of the patients were with normal karyotype and BM blast cells range 5.6 13.8%. The highest rate of AML transformation was in the patients group with BM marrow percentage >10%, poor karyotype and high IPSS risk. Major independent variable for AML evolution indicated by the multivariate analyses was the percentage of bone marrow blast cells. We supposed the predictive potential of the BM blast cells is the result of biological heterogeneity of MDS patients and patients with <5% blast cells especially.
•
TRANSFUSION DEPENDENCY: INDEPENDENT PROGNOSTIC FACTOR FOR PATIENTS WITH MYELODYSPLASTIC SYNDROME
L. Wong, S. Dobin, D. Ladd, W. Koss, T. Wajima*. Hematology/Oncology, Texas A&M University Health Science Center & Scott and White Clinic, USA *E-maih [email protected] Most patients with myelodysplastic syndromes (MDS) present with anemia and a majority will eventually become transfusion-dependent with potential complications caused by blood transfusion. The study was aimed to find whether transfusion-dependency (TD) is an important prognostic factor in patients with MDS. Fifty-one MDS patients were studied retrospectively: median age 68 (range 46 85), 36 male, 15 female, 24 RA, 5 RARS, 16 RAEB, 6 RAEB-t, median follow-up time 2.3 years (range 0.2 12). TD was defined as requirement of at least one unit of packed red cell transfusion per month. Transfusion was done only on the basis of symptomatic anemia. Thirty-three patients (65%) had TD, and 18 (35%) had no TD. Among TD patients, 15 (48%) had a normal karyotype and 17 (52%) showed clonal aberrations (Intermediate 11, Poor 6). RA patients had 17%, RARS 40%, RAEB 68%, RAEBT 100% incidence of TD. TD group had higher IP S S, whereas non-TD had lower IPSS. TD group had shorter overall survival and 6 evolved to AML. All RAEB-t had TD, higher IPSS and poor karyotype. TD was correlated to FAB classification, karyotype analysis, IPSS and overall
Posters
Etiology, Prognosis
•
RELATIONSHIP BETWEEN GSTT1, GSTM1 AND NQO1 GENES POLYMORPHISMS AND MYELODYSPLASTIC S Y M D R O M E S
Z. Xiao*, L. Yang, X. Zou, Y. Zhang, M. Zhang, Y. Hao. Institute of Hematology, CA34S & PUMC, China *E-maih [email protected] To investigate the impact of GSTM1, GSTT1 and NQO1 genotypes on the myelodysplastic syndromes (MDS) susceptibility and chromosome abnormalities of MDS, we analyzed gene polymorphisms of glutathione Stransferase (GST)-M1 and GSTT1, and NAD(P)H: quinone oxidoreductase (NQO1), the enzymes of which are capable of metabolizing anticancer drugs, in 52 MDS patients and 241 controls by PCR or PCR-RFLP. The incidence of GSTT1 (67.3%) and GSTM1 (80%) null genotype were significantly increased in MDS patients as compared to controls (44.8% and 52.7%, respectively) (p 0.001 and p<0.001, respectively), in individuals with the GSTT1 and GSTM1 null genotype, the odds ratios for disease risk were elevated to 2.873 (95%CI: 1.491 5.537) and 3.591 (95%CI: 1.71%7.508), respectively. A significantly increased frequency of GSTT1 null genotype was found among MDS patients with normal karyotype compared to controls (P 0.005, OR 5.336), while the frequency of GSTM1 null genotype was significantly higher in MDS patients with chromosome abnormalities compared to controls (P 0.003, OR 3.740). There is no difference of the incidence of NQO1 genotypes between MDS patients and controls. These results suggest that determination of the GSTM1 and GSTT1 genotypes may be used as a stratification marker to predicate high-risk individuals for MDS and the chromosome abnormalities in MDS patients.
•
PROGNOSTIC VALUE OF BONE MARROW BLAST CELLS AND KARYOTYPE IN MYELODYSPLASTIC SYNDROME
S.V. Gritsaev*, I.S. Martinkevitch, S.A. Tyranova, M.R Bakaja, K.M. Abdulkadirov. Russian Institute of Hematology, Russia *E-maih haemat ology@at lant.ru The aim of the work was to examine the predictive value of the bone marrow blast cells and karyotype as the markers
of leukemic evolution. We reviewed retrospectively 72 previously diagnosed cases of primary MDS. The diagnoses were established according to the WHO criteria. Twentythree patients (31.9%) progressed to AML with the median interval of 9 months (range 1 74 months). Acute leukemia evolution of 10 patients (43.5%) was observed at the first 6 months after the diagnosis and four of the patients were with normal karyotype and BM blast cells range 5.6 13.8%. The highest rate of AML transformation was in the patients group with BM marrow percentage >10%, poor karyotype and high IPSS risk. Major independent variable for AML evolution indicated by the multivariate analyses was the percentage of bone marrow blast cells. We supposed the predictive potential of the BM blast cells is the result of biological heterogeneity of MDS patients and patients with <5% blast cells especially.
•
TRANSFUSION DEPENDENCY: INDEPENDENT PROGNOSTIC FACTOR FOR PATIENTS WITH MYELODYSPLASTIC SYNDROME
L. Wong, S. Dobin, D. Ladd, W. Koss, T. Wajima*. Hematology/Oncology, Texas A&M University Health Science Center & Scott and White Clinic, USA *E-maih [email protected] Most patients with myelodysplastic syndromes (MDS) present with anemia and a majority will eventually become transfusion-dependent with potential complications caused by blood transfusion. The study was aimed to find whether transfusion-dependency (TD) is an important prognostic factor in patients with MDS. Fifty-one MDS patients were studied retrospectively: median age 68 (range 46 85), 36 male, 15 female, 24 RA, 5 RARS, 16 RAEB, 6 RAEB-t, median follow-up time 2.3 years (range 0.2 12). TD was defined as requirement of at least one unit of packed red cell transfusion per month. Transfusion was done only on the basis of symptomatic anemia. Thirty-three patients (65%) had TD, and 18 (35%) had no TD. Among TD patients, 15 (48%) had a normal karyotype and 17 (52%) showed clonal aberrations (Intermediate 11, Poor 6). RA patients had 17%, RARS 40%, RAEB 68%, RAEBT 100% incidence of TD. TD group had higher IP S S, whereas non-TD had lower IPSS. TD group had shorter overall survival and 6 evolved to AML. All RAEB-t had TD, higher IPSS and poor karyotype. TD was correlated to FAB classification, karyotype analysis, IPSS and overall